Sigilon
100 Binney St
STE 600
Cambridge
Massachusetts
02142
United States
Website: http://sigilon.com/
Email: info@sigilon.com
41 articles about Sigilon
-
Eli Lilly announced Thursday it will acquire former collaborative partner Sigilon Therapeutics to deepen its diabetic foothold with a potentially functional cure for Type 1.
-
Sigilon Announces Reverse Stock Split of Common Stock
5/22/2023
Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.
-
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
5/9/2023
Sigilon Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2023 as well as certain other business highlights.
-
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
4/18/2023
Sigilon Therapeutics, Inc. today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference.
-
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
11/10/2022
Sigilon Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 as well as certain other business highlights.
-
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8/4/2022
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the second quarter ended June 30, 2022 as well as certain other business highlights.
-
Sigilon Therapeutics to Present at the Needham Healthcare Conference
4/7/2022
Sigilon Therapeutics, Inc. today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will take place on Thursday, April 14, 2022 at 8:45 a.m. EDT.
-
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
3/8/2022
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference.
-
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
11/29/2021
Sigilon Therapeutics, Inc. today reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A.
-
Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
11/10/2021
Sigilon Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 as well as certain other business highlights.
-
Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference
11/9/2021
Sigilon Therapeutics, Inc. today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the upcoming Jefferies London Healthcare Conference.
-
Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development
7/19/2021
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development.
-
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A
7/9/2021
Sigilon Therapeutics, Inc. today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A, has been placed on clinical hold.
-
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer
6/14/2021
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer.
-
Sigilon Therapeutics to Present at the BofA Securities 2021 Healthcare Conference
5/6/2021
Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the BofA Securities 2021 Healthcare Conference.
-
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
4/8/2021
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 20th Annual Needham Virtual Healthcare Conference.
-
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
3/5/2021
Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease.
-
Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™
2/8/2021
Results demonstrate potential of Company’s therapies developed using its novel Shielded Living Therapeutics™ platform to treat broad range of chronic diseases
-
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
12/17/2020
Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIG-005 for the treatment of mucopolysaccharidosis type I (MPS-1), a chronic, progressive lysosomal storage disease.
-
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.